VS-7375 (GFH375): An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination...

CrozrX· @CrozrX · X·2026-04-20 21:10· 2026-04-20Score60

Body · original

VS-7375 (GFH375): An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents.

Is this triplet (VS-7375 defactinib and avutometinib) happening
@DavidHongMD
?

@AACR

@ElizSMcKenna

@KRASKickers
#AACR26

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts

6386matched by 药名 avutometinib

Small bowel obstruction and short bowel syndrome may impair the efficacy of Avutometinib and Defactinib in recurrent low grade serous ovarian cancer: A case report.

Sarah Ottum, Luca Palmieri, Victoria Ettorre, Tobias Hartwich, Cem Demirkiran, Namrata Sethi, Stefania Bellone, Alessandro D. Santin

Read the abstract →

LB183matched by 代号 VS-7375

Strong durable tumor regressions with the KRASG12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRASG12D-mutant pancreatic cancer

Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

Read the abstract →

LB197matched by 代号 VS-7375

VS-7375, a non-covalent dual ON/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancer

Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

Read the abstract →

7100NCT06500676 NCT07020221matched by 代号 VS-7375

VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents

Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter

Read the abstract →

Source: CrozrX · x.com